GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vincerx Pharma VINC · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.02

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Vincerx Pharma

Its shares trade under the ticker VINC. It has been listed since 10 March 2020.

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California. The company went IPO on 2020-03-10. The Company’s pipeline consists of enitociclib, which is in Phase I, and a modular bioconjugation platform, which includes a small molecule drug-conjugate (SMDC), VIP236, in Phase I, and preclinical next-generation antibody drug-conjugates, VIP943 and VIP924. Enitociclib, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. The firm's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. VIP236 is a SMDC with a focus on treating patients with cancers.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
10 Mar 2020
Employees
41
Website
vincerx.com ↗

Leadership

Pay as last reported

  • Dr. Raquel IzumiActing Chief Executive Officer, Director, since 2020$1.8m
  • Mr. Kevin HaasActing Chief Financial Officer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
50
Environment
51
Social
76
Governance
24
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Vincerx Pharma employs 41 full-time staff members in Palo Alto.
  • The pipeline includes enitociclib, a selective CDK9 inhibitor in Phase I.
  • The company developed VIP236, an SMDC targeting solid tumors in Phase I.

Weaknesses

  • The firm has only 41 employees, limiting operational scale significantly.
  • Enitociclib remains in early Phase I clinical trials without results.
  • VIP943 and VIP924 are still in preclinical stages of development.

Opportunities

  • Advancing VIP236 could expand treatment options for patients with solid tumors.
  • Developing next-generation ADCs like VIP943 offers potential in oncology markets.
  • IPO listing on 10 March 2020 provides capital for clinical trials.

Threats

  • Phase I trials for enitociclib may fail to show efficacy.
  • Preclinical status of VIP924 poses risks for future commercialization.
  • Competitive landscape in biotechnology may hinder market entry for ADCs.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.